1
228
T. Q. FROES ET AL.
diones carboxamide and amino acid derivatives. Molecules
2,4-diones and 3-substituted-4-thio-imidazolidine-2-ones.
2019;25:105–17.
Ann Pharm Fr 1995;53:209–14.
3
3
3
6. Tahlan S, Verma PK. Synthesis, SAR and in vitro therapeutic 52. Grøftehauge MK, Hajizadeh NR, Swann MJ, Pohl E. Protein-
potentials of thiazolidine-2,4-diones. Chem Cent J 2018;12:
–11.
7. Liu Y, Li R, Xing Y. A simple, efficient and green procedure
ligand interactions investigated by thermal shift assays (TSA)
and dual polarization interferometry (DPI). Acta Crystallogr D
Biol Crystallogr 2015;71:36–44.
1
for knoevenagel condensation in hydroxy-functionalized 53. Lea WA, Simeonov A. Differential scanning fluorometry sig-
ionic liquids. Heterocycles 2015;91:1385–97.
8. De Paiva RKC, Da Silva JF, Moreira HA, et al. Synthesis, anti-
microbial activity and structure-activity relationship of some
natures as indicators of enzyme inhibitor mode of action:
case study of glutathione s-transferase. PLOS One 2012;7:
e36219.
5-arylidene-thiazolidine-2,4-dione derivatives. J Braz Chem
5
5
5
5
5
4. Bai N, Roder H, Dickson A, Karanicolas J. Isothermal analysis
of thermofluor data can readily provide quantitative binding
affinities. Sci Rep 2019;9:2650–15.
5. The TH, Feltkamp TEW. Conjugation of fluorescein isothio-
cyanate to antibodies I. Experiments on the conditions of
conjugation. Immunology 1970;18:865–73.
6. Vivoli M, Novak HR, Littlechild JA, Harmer NJ. Determination
of protein-ligand interactions using differential scanning flu-
orimetry. J Vis Exp 2014;91:1–13.
Soc 2018;30:164–72.
3
9. Khan FAK, Patil RH, Shinde DB, Sangshetti JN. Design and
synthesis of 4’-((5-benzylidene-2,4-dioxothiazolidin-3-yl)me-
thyl)biphenyl-2-carbonitrile analogs as bacterial peptide
deformylase inhibitors. Chem Biol Drug Des 2016;88:938–44.
0. Azad L, Ghazvini M, Sanaeishoar H, Yavari I. Synthesis of
functionalized 1,2-dihydroisoquinolines via one-pot reactions
of isoquinoline, alkyl propiolate, and thiazolidin-2,4-dione. J
Chem Res 2019;43:457–60.
4
7. Cimmperman P, Baranauskiene L, Jachimovici uꢃ te S, et al. A
4
4
4
1. Da Silva IM, Da Silva Filho J, Santiago P, et al. Synthesis and
antimicrobial activities of 5-arylidene-thiazolidine-2,4- dione
derivatives. Biomed Res Int 2014;2014:316082.
2. Zhang Y, Zhou Z. A solvent-free protocol for the green syn-
thesis of 5-arylidene-2,4-thiazolidinediones using ethylenedi-
amine diacetate as catalyst. Org Chem Int 2012;2012:1–5.
3. Sharma H, Lather V, Grewal AS, Pandita D. Synthesis, anti-
inflammatory activity and docking studies of some newer
quantitative model of thermal stabilization and destabiliza-
tion of proteins by ligands. Biophys J 2008;95:3222–31.
8. Niesen FH, Schultz L, Jadhav A, et al. High-affinity inhibitors
of human NADþ-dependent 15-hydroxyprostaglandin
dehydrogenase: mechanisms of inhibition and structure-
activity relationships. PLoS One 2010;5:e13719.
5
6
9. Auld DS, Lovell S, Thorne N, et al. Molecular basis for the
high-affinity binding and stabilization of firefly luciferase by
PTC124. Proc Natl Acad Sci U S A 2010;107:4878–83.
0. Simeonov A. Recent developments in the use of differential
scanning fluorometry in protein and small molecule discov-
ery and characterization. Expert Opin Drug Discov 2013;8:
1
,3-thiazolidine-2,4-dione derivatives as dual inhibitors of
PDE4 and PDE7. Curr Comput Aided Drug Des 2019;15:
25–34.
2
4
4
4
4. Mohanty S, Roy AK, Sandeep Reddy G, et al. Knoevenagel
condensation of aromatic bisulfite adducts with 2,4-thiazoli-
dinedione in the presence of Lewis acid catalysts.
Tetrahedron Lett 2015;56:2564–7.
5. Palkar M, Jalalpure S, Rane R, et al. novel series of coumar-
inyl substituted-thiazolidin-2,4-dione analogs as anticancer
agents: design, synthesis, spectral studies and cytotoxicity
evaluation. Anticancer Agents Med Chem 2015;15:970–9.
6. Kaarsholm B, Christian N, Olsen B. Preparation of novel
ligands for the HisB10 Zn2þ sites of the R-state insulin hex-
amer and their use in pharmaceutical preparations compris-
ing insulin. PCT Int. Appl. 2006;3–7:WO 2006082245 A1
1
–20.
6
6
1. World Health Organization. . Antibacterial agents in clinical
2. Renwick MJ, Brogan DM, Mossialos E. A systematic review
and critical assessment of incentive strategies for discovery
and development of novel antibiotics. J Antibiot 2016;69:
7
3–88.
6
6
3. Renwick M, Mossialos E. What are the economic barriers of
antibiotic R&D and how can we overcome them? Expert
Opin Drug Discov 2018;13:889–92.
4. Dheman N, Mahoney N, Cox EM, et al. An analysis of anti-
bacterial drug development trends in the United States,
20060810.
4
4
4
5
5
7. Chandrappa S, Vinaya K, Prasanna DS, Rangappa KS. Mild
and highly efficient method for the synthesis of arylidene-
thiazolidinone analogues. Proc Indian Natl Sci Acad 2011;77:
1
980–2019. Clin Infect Dis 2020;72:1–7.
343–9.
6
6
5. Hoffman PS. Antibacterial discovery: 21st century challenges.
Antibiotics 2020;9:1–10.
6. Calvert MB, Jumde VR, Titz A. Pathoblockers or antivirulence
drugs as a new option for the treatment of bacterial infec-
tions. Beilstein J Org Chem 2018;14:2607–17.
8. Sato S, Shirakawa S, Tatsui A, et al. Thiazolidine derivatives
as chymase inhibitors and prophylactic and therapeutic
drugs containing them for cardiovascular diseases. Jpn
Kokai Tokkyo Koho 2000; JP 2000095770 A 20000404.
9. Maccari R, Ottan ꢂa R, Curinga C, et al. Structure-activity rela-
6
7. DIckey SW, Cheung GYC, Otto M. Different drugs for bad
bugs: antivirulence strategies in the age of antibiotic resist-
ance. Nat Rev Drug Discov 2017;16:457–71.
tionships and molecular modelling of 5-arylidene-2,4-thiazo-
lidinediones active as aldose reductase inhibitors. Bioorg
Med Chem 2005;13:2809–23.
0. Libermann D, Himbert J. HL. La thiazolidione, point de 68. Inglis RF, Brown SP, Buckling A. Spite versus cheats: compe-
depart d’une synth ꢂe se des acides thiopyruviques et thio-
glyoxiliques substitu eꢂ es. Bull Soc Chim Fr 1948;11–12:
tition
among
social
strategies
shapes virulence.
Pseudomonas Aeruginosa. Evolution 2012;66:3472–84.
69. El-halfawy OM, Czarny TL, Flannagan RS, et al. Discovery of
an antivirulence compound that reverses b-lactam resistance
in MRSA . Nat Chem Biol 2020;16:143–9.
1120–4.
1. Albuquerque JF, Azevedo LC, Galdino SL, Chantegrel J, et al.
Synthesis and structural study of 5-arylidene thiazolidine-